EP 2167544 A2 20100331 - MONOCLONAL ANTIBODY DIRECTED AGAINST THE HUMAN LDL RECEPTOR
Title (en)
MONOCLONAL ANTIBODY DIRECTED AGAINST THE HUMAN LDL RECEPTOR
Title (de)
GEGEN DEN HUMANEN LDL-REZEPTOR GERICHTETER MONOKLONALER ANTIKÖRPER
Title (fr)
ANTOCORPS MONOCLONAL DIRIGE CONTRE LE RECEPTEUR HUMAIN DES LDL
Publication
Application
Priority
- FR 2007002187 W 20071228
- FR 0611546 A 20061229
Abstract (en)
[origin: FR2910896A1] Monoclonal antibody directed against human low-density lipoprotein receptor comprises light chain variable regions encoded by a defined murine nucleic acid sequence, heavy chain variable regions encoded by a defined murine nucleic acid sequence, and light and heavy chain constant regions derived from a nonmurine species. Monoclonal antibody directed against human low-density lipoprotein receptor comprises light chain variable regions encoded by murine nucleic acid sequence SEQ ID NO:5 (defined sequence of 336 nucleotides given in the specification), heavy chain variable regions encoded by murine nucleic acid sequence SEQ ID NO:7 (defined sequence of 345 nucleotides given in the specification), and light and heavy chain constant regions derived from a nonmurine species. Independent claims are also included for: (1) vector for expressing the light chain of an antibody as above, with SEQ ID NO:12 (defined sequence of 6288 nucleotides given in the specification); (2) vector for expressing the heavy chain of an antibody as above, with SEQ ID NO:18 (defined sequence of 6717 nucleotides given in the specification); (3) stable cell line producing the antiibody; (4) DNA fragment with SEQ ID NO:19 (defined sequence of 1341 nucleotides given in the specification) coding for the heavy chain of the antibody; (5) DNA fragment with SEQ ID NO:13 (defined sequence of 663 nucleotides given in the specification) coding for the light chain of the antibody; (6) use of a monoclonal antibody directed against human low-density lipoprotein receptor for preparing a medicament for treating melanoma. ACTIVITY : Cytostatic. MECHANISM OF ACTION : Immunotherapy.
IPC 8 full level
C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC (source: EP KR US)
A61K 39/395 (2013.01 - KR); A61P 35/00 (2017.12 - EP); C07K 16/28 (2013.01 - EP KR US); C07K 16/2833 (2013.01 - EP US); C07K 16/30 (2013.01 - KR); C07K 2317/24 (2013.01 - EP US); C07K 2317/56 (2013.01 - EP US); C07K 2317/72 (2013.01 - EP US); C07K 2317/73 (2013.01 - EP US); C07K 2317/732 (2013.01 - EP US); C07K 2317/75 (2013.01 - EP US)
Citation (search report)
See references of WO 2008099071A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK RS
DOCDB simple family (publication)
FR 2910896 A1 20080704; FR 2910896 B1 20121116; AU 2007346741 A1 20080821; CA 2661853 A1 20080821; CN 101679524 A 20100324; EP 2167544 A2 20100331; JP 2010514434 A 20100506; KR 20100014279 A 20100210; US 2010098706 A1 20100422; WO 2008099071 A2 20080821; WO 2008099071 A3 20081218; WO 2008099071 A8 20091022
DOCDB simple family (application)
FR 0611546 A 20061229; AU 2007346741 A 20071228; CA 2661853 A 20071228; CN 200780048492 A 20071228; EP 07872460 A 20071228; FR 2007002187 W 20071228; JP 2009543504 A 20071228; KR 20097013066 A 20071228; US 51927507 A 20071228